PetMed Express Inc (PETS)
Official siteHEALTHCARE • PHARMACEUTICAL RETAILERS • NASDAQ
Market Cap: $20.90M
Last updated: Nov 17, 2026 at 11:03 AM ET
PetMed Express Inc (PETS) Earnings: Report Dates and Results
PetMed Express (PETS) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, PetMed Express reported EPS of -$0.31, below the -$0.11 estimate. It beat the EPS estimate in 0 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PETS has an expected report date of Feb 3, 2027.
PETS Earnings Call
The latest PETS earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PETS beat 14, missed 25 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $35.77M, down 19.4% from $44.36M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.31 | -$0.11 | -$0.11 - -$0.11 | -181.82% | Miss | N/A | 1 | 0 up, 1 down | Nov 10, 2026 | $35.77M |
| Jun 30, 2026 | -$0.28 | $0.12 | $0.12 - $0.12 | -333.33% | Miss | N/A | 1 | 0 up, 0 down | Jul 27, 2026 | $41.02M |
| Mar 31, 2026 | -$0.19 | -$0.18 | -$0.18 - -$0.18 | -5.56% | Miss | N/A | 1 | 0 up, 1 down | Jun 2, 2026 | $42.82M |
| Dec 31, 2025 | -$0.50 | -$0.06 | -$0.06 - -$0.06 | -733.33% | Miss | N/A | 1 | 0 up, 1 down | Feb 5, 2026 | $40.66M |
| Sep 30, 2025 | -$0.56 | -$0.49 | N/A | -14.29% | Miss | -609.1% | 1 | 0 up, 1 down | Dec 19, 2025 | $44.36M |
| Jun 30, 2025 | -$0.06 | $0.21 | N/A | -128.57% | Miss | -133.3% | 1 | 1 up, 0 down | Aug 11, 2025 | $51.18M |
| Mar 31, 2025 | -$0.34 | -$0.04 | N/A | -750.00% | Miss | N/A | 1 | 0 up, 1 down | Jun 9, 2025 | $50.76M |
| Dec 31, 2024 | -$0.03 | $0.01 | N/A | -400.00% | Miss | N/A | N/A | 0 up, 0 down | Feb 10, 2025 | $51.96M |
| Sep 30, 2024 | $0.11 | -$0.05 | -$0.06 - -$0.05 | +320.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 6, 2024 | $58.04M |
| Jun 30, 2024 | $0.18 | -$0.09 | -$0.12 - -$0.06 | +300.00% | Beat | +80.0% | 2 | 0 up, 0 down | Aug 6, 2024 | $66.21M |
| Mar 31, 2024 | -$0.25 | -$0.07 | -$0.07 - -$0.07 | -257.14% | Miss | N/A | 1 | 0 up, 0 down | Apr 15, 2024 | $59.53M |
| Dec 31, 2023 | -$0.10 | -$0.01 | -$0.03 - $0.01 | -900.00% | Miss | -600.0% | 2 | 0 up, 0 down | Feb 8, 2024 | $65.32M |
| Sep 30, 2023 | $0.00 | $0.09 | -$0.01 - $0.18 | -103.78% | Miss | -102.0% | 2 | 0 up, 0 down | Oct 30, 2023 | $71.00M |
| Jun 30, 2023 | $0.10 | $0.07 | $0.06 - $0.09 | +42.86% | Beat | -33.3% | 3 | 0 up, 2 down | Jul 31, 2023 | $78.24M |
| Mar 31, 2023 | -$0.25 | $0.14 | $0.10 - $0.20 | -278.57% | Miss | -183.3% | 3 | 0 up, 1 down | May 22, 2023 | $53.40M |
| Dec 31, 2022 | $0.02 | $0.17 | $0.17 - $0.22 | -88.24% | Miss | -90.5% | 3 | 0 up, 0 down | Feb 6, 2023 | $58.87M |
| Sep 30, 2022 | $0.17 | $0.26 | $0.22 - $0.30 | -34.62% | Miss | -45.2% | 3 | 0 up, 0 down | Nov 7, 2022 | $65.26M |
| Jun 30, 2022 | $0.15 | $0.23 | $0.21 - $0.30 | -34.78% | Miss | -34.8% | 3 | 0 up, 1 down | Jul 25, 2022 | $70.04M |
| Mar 31, 2022 | $0.30 | $0.28 | $0.24 - $0.29 | +7.14% | Beat | -11.8% | 3 | 0 up, 1 down | May 9, 2022 | $64.87M |
| Dec 31, 2021 | $0.21 | $0.32 | $0.32 - $0.35 | -34.38% | Miss | -44.7% | 2 | 0 up, 0 down | Jan 24, 2022 | $60.72M |
| Sep 30, 2021 | $0.31 | $0.35 | $0.34 - $0.35 | -11.43% | Miss | -26.2% | 2 | N/A | Oct 25, 2021 | $67.39M |
| Jun 30, 2021 | $0.23 | $0.35 | $0.33 - $0.38 | -34.29% | Miss | -41.0% | 2 | N/A | Jul 26, 2021 | $79.31M |
| Mar 31, 2021 | $0.34 | $0.40 | $0.39 - $0.41 | -15.00% | Miss | -2.9% | 2 | N/A | May 3, 2021 | $66.05M |
| Dec 31, 2020 | $0.38 | $0.38 | $0.37 - $0.38 | 0.00% | In line | +11.8% | 2 | N/A | Jan 19, 2021 | $60.72M |
| Sep 30, 2020 | $0.42 | $0.40 | $0.37 - $0.42 | +5.00% | Beat | +27.3% | 2 | N/A | Oct 26, 2020 | $75.44M |
| Jun 30, 2020 | $0.39 | $0.40 | $0.33 - $0.46 | -2.50% | Miss | +50.0% | 2 | N/A | Jul 20, 2020 | $96.20M |
| Mar 31, 2020 | $0.35 | $0.29 | $0.23 - $0.35 | +20.69% | Beat | +9.4% | 2 | N/A | May 4, 2020 | $74.29M |
| Dec 31, 2019 | $0.34 | $0.30 | $0.27 - $0.32 | +13.33% | Beat | -10.5% | 2 | N/A | Jan 21, 2020 | $59.91M |
| Sep 30, 2019 | $0.33 | $0.26 | $0.22 - $0.31 | +26.92% | Beat | -36.5% | 3 | N/A | Oct 21, 2019 | $69.94M |
| Jun 30, 2019 | $0.26 | $0.42 | $0.30 - $0.62 | -38.10% | Miss | -58.1% | 3 | N/A | Jul 22, 2019 | $79.99M |
| Mar 31, 2019 | $0.32 | $0.46 | $0.40 - $0.53 | -30.43% | Miss | -36.0% | 3 | N/A | May 6, 2019 | $64.56M |
| Dec 31, 2018 | $0.38 | $0.48 | $0.47 - $0.49 | -20.83% | Miss | -13.6% | 3 | N/A | Jan 22, 2019 | $60.07M |
| Sep 30, 2018 | $0.52 | $0.50 | $0.49 - $0.51 | +4.00% | Beat | +20.9% | 4 | N/A | Oct 22, 2018 | $71.40M |
| Jun 30, 2018 | $0.62 | $0.63 | $0.61 - $0.64 | -1.59% | Miss | +37.8% | 5 | N/A | Jul 23, 2018 | $87.39M |
| Mar 31, 2018 | $0.50 | $0.47 | $0.44 - $0.53 | +6.38% | Beat | +35.1% | 4 | N/A | May 7, 2018 | $67.32M |
| Dec 31, 2017 | $0.44 | $0.31 | $0.26 - $0.37 | +41.94% | Beat | +83.3% | 4 | N/A | Jan 22, 2018 | $60.11M |
| Sep 30, 2017 | $0.43 | $0.30 | $0.25 - $0.35 | +43.33% | Beat | +79.2% | 5 | N/A | Oct 23, 2017 | $66.71M |
| Jun 30, 2017 | $0.45 | $0.38 | $0.33 - $0.40 | +18.42% | Beat | +40.6% | 4 | N/A | Jul 24, 2017 | $79.66M |
| Mar 31, 2017 | $0.37 | $0.26 | N/A | +42.31% | Beat | +37.0% | N/A | N/A | May 8, 2017 | $63.03M |
| Dec 31, 2016 | $0.24 | $0.25 | N/A | -4.00% | Miss | 0.0% | N/A | N/A | Jan 23, 2017 | $52.87M |
Annual EPS
EPS for the fiscal year ended Mar 31, 2026 was -$1.31, after -$0.08 the year before. It was $1.17 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Mar 31, 2026 | -$1.31 | N/A |
| Mar 31, 2025 | -$0.08 | N/A |
| Mar 31, 2024 | -$0.25 | -381.6% |
| Mar 31, 2023 | $0.09 | -91.4% |
| Mar 31, 2022 | $1.05 | -31.4% |
| Mar 31, 2021 | $1.53 | +19.5% |
| Mar 31, 2020 | $1.28 | -30.4% |
| Mar 31, 2019 | $1.84 | N/A |
| Mar 31, 2018 | $1.82 | +55.6% |
| Mar 31, 2017 | $1.17 | N/A |
Earnings Calls
The 4 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 3,400 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 3,444 | 6 | |
| 2025Q2 | Jun 30, 2025 | 2,695 | 5 | |
| 2025Q1 | Mar 31, 2025 | 3,564 | 5 | |
| 2024Q4 | Dec 31, 2024 | 4,536 | 6 |
2025Q3 Earnings Call
Opening remarks
Reed Anderson Host Thank you, and welcome to the PetMed Express fiscal third quarter 2025 earnings conference call. Certain information included during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934 as amended that may involve a number of risks and uncertainties. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual results could differ materially from those projected. There can be no assurance that any forward-looking results will occur or be realized and nothing contained in this presentation is or should be relied upon as a representation or warranty as to any future matters, including any matter in respect of the operations or business or financial condition of PetMed. PetMed undertakes no obligation to update publicly these forward-looking statements based on subsequent events, except as may be required by applicable law, regulation or other competent legal authority. We've identified various risk factors associated with our operations in our most recent annual report and other filings with the Securities and Exchange Commission. Now, let me turn the call over to our CEO and President, Sandra Campos.
Sandra Campos CEO Thank you, Reed, and welcome to everyone joining our call this afternoon. Following my remarks, Robyn will provide a detailed overview of our financial results, after which we'll open the lines for your questions. Over the past nine months, I have emphasized that our focus remains steadfast on the strategic initiatives pivotal to repositioning PetMed and PetCareRx for long-term success. I have clearly outlined our vision to position PETS as a leader in consumer pet healthcare. While we're still in the early stages of this transformation and have much more work ahead, I am pleased to report that we have made significant progress in validating our strategic direction. We're confident that the actions we're taking will drive differentiation and sustainable growth. Our highest priority has been to return the company to profitability. We achieved this by implementing cost-cutting measures and consolidation strategies to integrate PetCareRx operations into the PetMed organization, targeting $5 million in annualized savings, and we remain on track to meet this milestone. For this quarter Q3, we achieved $2 million in adjusted EBITDA representing a $1.1 million improvement year-over-year while lowering G&A expenses by $2.6 million, compared to last year. As we continue to execute our turnaround strategy, we remain committed to driving shareholder value through growing our customer base, operational discipline, and financial efficiency. At PETS, we serve three core communities. First, our pet parents.
Frequently Asked Questions About PETS
When is PetMed Express's next earnings date?
PetMed Express's next earnings report is expected for Feb 3, 2027.
Did PETS beat earnings estimates last quarter?
No. PetMed Express reported EPS of -$0.31 for the quarter ended Sep 30, 2026, below the -$0.11 estimate by 181.82%.
What EPS do analysts expect from PETS next quarter?
The consensus EPS estimate for PetMed Express for the quarter ending Dec 31, 2026 is -$0.16 from 1 analyst, with estimates from -$0.16 to -$0.16.
How often does PETS beat earnings estimates?
PetMed Express beat the EPS estimate in 0 of the last 8 quarters, with an average surprise of -318.36%.
PETS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors